Prognostic Role of DFNA5 in Head and Neck Squamous Cell Carcinoma Revealed by Systematic Expression Analysis

Zhiguo Liu  
Sun Yat-Sen University

Hongyan Liu  
Sun Yat-Sen University

Qian Dong  
Sun Yat-Sen University

Hongyu Li  
Sun Yat-Sen University

Bin Zhang  
Sun Yat-Sen University

Yufeng Liu  
Guangzhou First People’s Hospital

Haikuo Tang (✉ tanghaikuo@163.com)  
Sun Yat-Sen University

Research Article

**Keywords:** DFNA5, head and neck cancer, survival prognosis, lymphocyte infiltration

**Posted Date:** December 4th, 2020

**DOI:** https://doi.org/10.21203/rs.3.rs-114898/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

The gasdermin E gene (GSDME, also known as DFNA5) is mutated in familial aging-related hearing loss. Recent studies have also revealed that the expression of DFNA5 is suppressed in many cancer types; however, little is known about the function of DFNA5 in head and neck squamous cell carcinoma (HNSCC). Accordingly, the aim of the present study was to evaluate the expression of DFNA5 and explore its prognostic value in HNSCC. We used a set of bioinformatics tools, including Oncomine, TIMER, TISIDB, cBioPortal, and GEPIA, to analyze the expression of DFNA5 in patients with HNSCC from public databases. Kaplan-Meier plotter was used to evaluate the potential prognostic significance of DFNA5. DFNA5 mRNA levels were significantly higher in HNSCC tissues than in normal tissues, and high DFNA5 expression was correlated with worse survival. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses showed that DFNA5 expression has a strong positive correlation with cell adhesion and the integrin signaling pathway, whereas its expression was negatively correlated with the levels of infiltrating B cells (cor = −0.223, P = 8.57e-07) and CD8 T cells (cor = −0.223, P = 2.99e-07). Overall, this study demonstrates that DFNA5 expression has prognostic value for HNSCC patients. Moreover, these results suggest that regulation of lymphocyte infiltration is the mechanism underlying the function of DFNA5 in HNSCC.

Introduction

Head and neck cancers include a wide variety of cancers varying in location and histological types. One of the subcategories is head and neck squamous cell carcinomas (HNSCCs), which include tumors of the nasal cavity, nasopharynx, oral cavity, oropharynx, hypopharynx, and larynx 1,2. Approximately 600,000 new cases of HNSCC are diagnosed each year worldwide, often at an advanced stage. Moreover, epidemiological data indicate that the incidence of oral cancer is increasing year after year 3. Although the use of combination therapy (i.e., surgical techniques, chemotherapy, and radiation therapy) has significantly improved local control and the overall quality of life of HNSCC patients, their survival rate has only increased slightly in the past 20 years 4. Therefore, it is imperative to understand the potential molecular carcinogenic pathways of HNSCC, which is expected to identify markers that can help to improve the diagnosis, treatment, and prevention of the disease.

Gasdermin E (GSDME), also known as deafness autosomal dominant 5 (DFNA5), was identified as a gene involved in an autosomal dominant form of inherited hearing impairment in 1998 5. Interestingly, subsequent reports showed that DFNA5 also plays a role in tumor biology. Specifically, DFNA5 has been suggested to act as a tumor suppressor, since it was shown to inhibit the colony formation and cell proliferation of gastric cancer, melanoma, and colorectal cancer cells, and could also suppress the aggressive behavior of breast cancer 6. Recently, some chemotherapeutic agents such as cisplatin 7, L61H10 8, and lobaplatin 9 were shown to be effective against esophageal cancer, lung cancer, and colon cancer, respectively, by inducing a DFNA5-dependent pyroptosis effect. These results have led to a new
understanding of cancer chemotherapy, while indicating that DFNA5 is a potential target for cancer treatment. However, the role of DFNA5 in HNSCC development and progression remains unknown.

In this work, we applied a wide range of comprehensive bioinformatics tools to assess the expression levels and potential function of DFNA5, as well as determine its prognostic value in human HNSCC.

Materials And Methods

1.1 Oncomine

Oncomine (https://www.oncomine.org/resource/login.html) is a publicly accessible online cancer microarray database that can be used for research related to genome-wide expression analysis. We used this database to extract data on the DFNA5 mRNA levels (log2-transformed) in HNSCC and neighboring normal tissues. The criteria for identifying a significant difference were a P-value < 1E-4, fold change >2, and the gene ranks in the top 10%

1.2 TIMER

TIMER is a web server for the comprehensive analysis of tumor-infiltrating immune cells. It offers six tumor-infiltrating immune subsets precalculated for 10,897 tumors from 32 cancer types (https://cistrome.shinyapps.io/timer/) 11.

1.3 TISIDB

TISIDB is an integrated repository portal for tumor-immune system interactions, which can also be used for the systematic testing of molecular features of such interactions (http://cis.hku.hk/TISIDB/) 12.

1.4 cBioPortal

cBioPortal includes tools for the visualization, analysis, and downloading of large-scale cancer genomics datasets. We used cBioPortal to identify genes positively related to DFNA5 expression in HNSCC 13.

1.5 GEPIA

GEPIA (http://gepia.pku.cn/) is a web server for analyzing RNA-sequencing (RNA-seq) data from tumors and neighboring normal tissues deposited in The Cancer Genome Atlas (TCGA) and the GTEx project. GEPIA also facilitates differential expression and survival analyses 14.
1.6 Kaplan-Meier plotter

Kaplan-Meier plotter (http://kmplot.com/analysis/) was used to evaluate the potential prognostic significance of *DFNA5*\(^5\). The hazard ratio (HR) with a 95% confidence interval and the P-value (log-rank) were calculated.

1.7 Cytoscape

Cytoscape (version 3.4.0) is an open-source bioinformatics software tool for visualizing molecular interaction networks. Its plug-in, MCODE, is used for ranking nodes in a network according to their network features\(^6\).

1.8 DAVID

DAVID (http://david.abcc.ncifcrf.gov/) is a tool that is widely used to reveal the biological significance of gene groups. After selecting co-expressed genes, Gene Ontology (GO) analysis was performed to assess their associated biological processes (BP), cellular components (CC), and molecular functions (MF)\(^7\). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database was used to identify biological pathways enriched with the co-expressed genes\(^8\).

1.9 UALCAN

UALCAN (http://ualcan.path.uab.edu) is an interactive web resource that can combine clinical data for 31 cancer types with corresponding RNA-seq data from the TCGA database. As such, it can be used to analyze relative gene transcript levels between tumors and normal samples, and the relationship between these levels and clinicopathological parameters\(^9\).

Results

1.1 *DFNA5* expression is upregulated in human HNSCC

The analysis of microarray data from HNSCC and adjacent normal tissues in the Oncomine database showed that *DFNA5* expression was upregulated in HNSCC (Figure 1A). This pattern was confirmed by the analysis of gene expression data deposited in TIMER (Figure 1B) and the transcriptome sequencing data from TCGA analyzed with GEPIA (Figure 1C, D). In addition to bulk analysis of HNSCC data, we also used Oncomine to compare *DFNA5* expression in healthy and cancer tissues from datasets corresponding to different HNSCC subtypes. These results showed that *DFNA5* upregulation is a general characteristic of HNSCC (Figure 1E–I). Further subgroup analysis of various clinicopathological features of HNSCC patients from the TCGA database revealed that in subgroup analyses based on gender, age,
race, disease stage, tumor grade, human papillomavirus infection, and nodal metastasis status, the transcription level of \textit{DFNA5} in HNSCC patients was consistently significantly higher than that in healthy subjects (Figure 2).

Furthermore, we used HNSCC cell lines for \textit{in vitro} validation, demonstrating a significant increase in the level of \textit{DFNA5} compared to that of control cells (Figure 2I). Collectively, these results suggest that the expression of \textit{DFNA5} may be a potential diagnostic marker of HNSCC.

\subsection*{1.2 High \textit{DFNA5} expression predicts poor prognosis in HNSCC patients}

We speculated that the expression of \textit{DFNA5} is related to the prognosis of HNSCC patients. To test this hypothesis, we evaluated the prognostic value of \textit{DFNA5} using the Kaplan-Meier plotter, TISIDB, and UALCAN (Figure 3A–C, respectively). All three analyses showed that high \textit{DFNA5} expression levels are associated with a poor prognosis in HNSCC patients. Moreover, this association was consistent regardless of tumor grade (Figure 3D), race (Figure 3E), or gender (Figure 3F).

To further understand this correlation and assess the potential underlying mechanism, we utilized the Kaplan-Meier plotter to explore the relationship between the \textit{DFNA5} expression level and specific clinical characteristics of HNSCC patients. As shown in Table 1, high expression of \textit{DFNA5} was significantly correlated with worse overall survival (OS) only in male patients (P = 0.041). Moreover, racial background did not have a statistically significant effect. With respect to tumor stage, \textit{DFNA5} overexpression was associated with poorer OS in HNSCC patients at all stages except for stage 3. More importantly, we found that high expression of \textit{DFNA5} corresponded with a worse OS in patients whose tumors were infiltrated by immune cells such as basophils, B-cells, T-cells, and macrophages (Table 1). These results suggest that \textit{DFNA5} may be a reliable biomarker for HNSCC prognosis, at least in male patients.

\subsection*{1.3 \textit{DFNA5} regulates cell adhesion in HNSCC}

Lists of the top 200 genes co-expressed with \textit{DFNA5} were created by analyzing TGCA datasets with cBioPortal (Figure 4A) and UALCAN (Figure 4B). Comparison of the two lists revealed 125 common co-expressed genes (Figure 4C). DAVID was then used to perform functional annotation of these 125 genes. GO analysis indicated that these genes were mainly involved in biological processes of locomotion, cell adhesion, and cell migration (Figure 4D), which was consistent with the enrichment in the respective cellular components and the proposed molecular functions (Figure 4E-F). In addition, KEGG pathway analysis showed enrichment in pathways of focal adhesion and the interaction between the actin cytoskeleton and the extracellular matrix receptor (Figure 4G). Collectively, these data suggest an essential role of \textit{DFNA5} in regulating cell adhesion in HNSCC.
1.4 Identification and analysis of *DFNA5*-related hub genes

CytoHubba, a Cytoscape plug-in, was used to identify potential hub genes for *DFNA5* function based on the density of maximum neighborhood component. The top 10 genes in the network included *ITGB1*, *ITGA3*, *ITGB4*, *ITGA6*, *PXN*, *ITGA5*, *LAMC2*, *LAMA3*, *PLEC*, and *LAMB3* (Figure 5A). GEPIA was then used to analyze the expression level of each hub gene and its correlation with OS. All genes except for *PLEC* had higher expression levels in HNSCCs than in normal tissues. Moreover, high expression levels of *ITGB1*, *LAMA3*, *PLEC*, and *LAMB3* correlated with poor OS in HNSCC patients (Figure 5B–K). These results further support that *DFNA5* mainly affects tumor progression in HNSCC by regulating cell adhesion through processes such as integrin-related molecular pathways.

1.5 High *DFNA5* expression results in decreased lymphocyte infiltration in HNSCC

To further explore the function of *DFNA5* in HNSCC and its prognostic potential, we focused on the infiltration of immune cells in the HNSCC tumor microenvironment. Specifically, we used TIMER to investigate whether the expression of *DFNA5* is related to the level of immune cell infiltration. Figure 6A shows that the *DFNA5* expression level was significantly negatively correlated with the infiltration of lymphocytes in HNSCC, such as B cells (cor = −0.223, P = 8.57e-07) and CD8 T cells (cor = −0.223, P = 2.99e-07). Furthermore, we analyzed the correlation between *DFNA5* expression levels and various immune cell markers in HNSCC, including subsets of T cells, B cells, M1 and M2 macrophages, neutrophils, natural killer cells, and dendritic cells. The results showed that the *DFNA5* expression level was significantly negatively correlated with B cell and CD8 T cell markers (Figure 6B). We conclude that a high level of *DFNA5* expression significantly correlates with decreased tumor local lymphocyte infiltration, which is an important negative prognostic factor in HNSCC patients.

Discussion

HNSCCs are aggressive cancers originating from the epithelial mucosa of the digestive tract. Although many studies have focused on the macro-genomic differences underlying the heterogeneity of these cancers, the survival rate of patients has not improved in the past decade. Here, we showed that *DFNA5* exerts oncogenic effects in HNSCC, as it is consistently overexpressed in cancer tissues and is an indicator of poor prognosis. Moreover, GO and KEGG pathway analyses showed that the upregulation of *DFNA5* in HNSCC mainly affects cell adhesion by regulating processes such as integrin binding. These results are consistent with the fact that two cell-to-cell adhesion genes that act as tumor suppressors, namely *CTNNA2* and *CTNNA3*, are frequently mutated in laryngeal carcinoma. These adhesion proteins and their related pathways provide new candidate targets for formulating novel therapeutic strategies.
This study suggests that DFNA5 plays an important role in the regulation of the recruitment and infiltration of immune cells in HNSCC. Changes in the immune system of HNSCC patients suggest that tumorigenesis is a comprehensive immunosuppressive process. In the peripheral blood, the overall number of white blood cells in patients with HNSCC is decreased, and inhibitory T cells (Treg) become dominant among them. Moreover, tumor-infiltrating lymphocytes (TILs) have been detected in many types of solid tumors, including HNSCCs. In HNSCC patients, TILs have stronger anti-cancer activity than peripheral blood Treg cells. Recent studies have shown that B cells and plasma B cells located in tumors or the tumor-draining lymph nodes play an important role in the formation of anti-tumor immune responses. Moreover, T cells and B cells interact and coordinate their selection, specialization, and clonal expansion in tumor-associated tertiary lymphoid structures; the resulting plasma B cells are crucial to the anti-tumor immune response. As TILs are a major factor in this process, it comes as no surprise that their immunoprofile is a prognostic marker of disease-specific survival. For example, in colorectal cancer, higher CD8/CD4 ratios are associated with longer disease-free survival. We found that DFNA5 expression was significantly negatively correlated with lymphocyte infiltration, especially of B cells and CD8+ T cells, suggesting that DFNA5 overexpression may exert its oncogenic function by hindering the anti-tumor immune response.

Notably, in contrast to our findings for HNSCC, DFNA5 expression is suppressed in many cancers, and reduced DFNA5 levels are associated with decreased survival in patients with breast cancer, suggesting that DFNA5 might be a tumor suppressor. In fact, recently study determined that the expression level DFNA5 in breast cancer patients was significantly decreased; therefore, we speculate that DFNA5 plays a different role in different tumor types.

In conclusion, this is the first study to report DFNA5 as a new biomarker for HNSCC. More importantly, our results suggest an underlying mechanism for the oncogenic function of DFNA5, namely the reduction of immune cell infiltration through the modulation of cell adhesion. With further understanding of its functional scope, DFNA5 may become an effective tool for the diagnosis and treatment of HNSCC, and may help to make biomarker therapy a promising therapeutic option.

**Declarations**

**Conflict of Interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Author Contributions**

The authors declare that they have no conflicts of interest.
All authors participated in the drafting of the article or its critical revision for important intellectual content and approved the publication of the final version of the manuscript. HT and YL had full access to all the study data and take responsibility for data integrity and the accuracy of data analysis results. ZL, HL, QD, HL and BZ contributed to the conception, study design, and data collection.

**Funding**

This study was supported by The National Nature Science Foundation of China (NSFC81672659, NSFC81472523), Guangzhou Science and Technology Program Project Collaborative Innovation Major Projects (201704020112), Guangdong Natural Science Foundation (2020A1515010291), and Guangdong Basic and Applied Basic Research Foundation (2020A1515010315).

**Data availability statement**

The data used to support the findings of this study are available from the corresponding author upon reasonable request. None of the data mentioned in the study is taken from any other source which is not publicly available.

**References**

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. *CA: a cancer journal for clinicians* **65**, 5-29 (2015).
2. Patel, J. *et al.* mTOR inhibitor use in head and neck squamous cell carcinoma: A meta-analysis on survival, tumor response, and toxicity. *Laryngoscope investigative otolaryngology* **5**, 243-255, doi:10.1002/lio2.370 (2020).
3. Cronin, K. A. *et al.* Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. *Cancer* **124**, 2785-2800 (2018).
4. Cramer, J. D., Burtness, B., Le, Q. T. & Ferris, R. L. The changing therapeutic landscape of head and neck cancer. *Nature Reviews Clinical Oncology* **16**, 669-683 (2019).
5. Van Laer, L. *et al.* Nonsyndromic hearing impairment is associated with a mutation in DFNA5. *Nature genetics* **20**, 194-197 (1998).
6. de Beeck, K., Van Laer, L. & Van Camp, G. DFNA5, a gene involved in hearing loss and cancer: a review. *The Annals of otology, rhinology, and laryngology* **121**, 197-207, doi:10.1177/000348941212100310 (2012).
7. Wu, M. *et al.* A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma. *EBioMedicine* **41**, 244-255 (2019).
8. Chen, L. et al. A thiopyran derivative with low murine toxicity with therapeutic potential on lung cancer acting through a NF-κB mediated apoptosis-to-pyroptosis switch. *Apoptosis* **24**, 74-82 (2019).

9. Yu, J. et al. Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells. *Cell death & disease* **10**, 1-20 (2019).

10. Toruner, G. A. et al. Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. *Cancer genetics and cytogenetics* **154**, 27-35 (2004).

11. Li, T. et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. *Cancer research* **77**, e108-e110 (2017).

12. Ru, B. et al. TISIDB: an integrated repository portal for tumor-immune system interactions. *Bioinformatics (Oxford, England)* **35**, 4200-4202, doi:10.1093/bioinformatics/btz210 (2019).

13. Gao, J. et al. (AACR, 2016).

14. Tang, Z. et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic acids research* **45**, W98-W102 (2017).

15. Hou, G.-X., Liu, P., Yang, J. & Wen, S. Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan–Meier plotter. *PloS one* **12** (2017).

16. Chin, C.-H. et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC systems biology* **8**, S11 (2014).

17. Dennis, G. et al. DAVID: database for annotation, visualization, and integrated discovery. *Genome biology* **4**, R60 (2003).

18. Consortium, G. O. The gene ontology (GO) project in 2006. *Nucleic acids research* **34**, D322-D326 (2006).

19. Chandrashekar, D. S. et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. *Neoplasia* **19**, 649-658 (2017).

20. Wenig, B. M. J. M. P. Squamous cell carcinoma of the upper aerodigestive tract: precursors and problematic variants. **15**, 229-254 (2002).

21. Rassouli, F. B., Matin, M. M. & Saeinasab, M. J. T. B. Cancer stem cells in human digestive tract malignancies. **37**, 7-21 (2016).

22. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. *Science* **333**, 1157-1160 (2011).

23. Fanjul-Fernández, M. et al. Cell–cell adhesion genes CTNNA2 and CTNNA3 are tumour suppressors frequently mutated in laryngeal carcinomas. *Nature communications* **4**, 1-9 (2013).

24. Yanagi, H. et al. CRKL plays a pivotal role in tumorigenesis of head and neck squamous cell carcinoma through the regulation of cell adhesion. *Biochemical and biophysical research communications* **418**, 104-109 (2012).

25. Song, J. et al. Novel-miR-4885 Promotes Migration and Invasion of Esophageal Cancer Cells Through Targeting CTNNA2. *DNA and cell biology* **38**, 151-161 (2019).
26. Jie, H. et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. *British journal of cancer* **109**, 2629-2635 (2013).

27. Duray, A., Demoulin, S., Hubert, P., Delvenne, P. & Saussez, S. Immune suppression in head and neck cancers: a review. *Clinical and Developmental Immunology* **2010** (2011).

28. Solomon, B., Young, R. J. & Rischin, D. in *Seminars in cancer biology*. 228-240 (Elsevier).

29. Yarchoan, M. et al. Effects of B cell–activating factor on tumor immunity. **5** (2020).

30. Bruno, T. New predictors for immunotherapy responses sharpen our view of the tumour microenvironment. *Nature* **577**, 474-476, doi:10.1038/d41586-019-03943-0 (2020).

31. Sharonov, G., Serebrovskaya, E., Yuzhakova, D., Britanova, O. & Chudakov, D. B cells, plasma cells and antibody repertoires in the tumour microenvironment. *Nature reviews. Immunology* **20**, 294-307, doi:10.1038/s41577-019-0257-x (2020).

32. Lalami, Y. & Awada, A. Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. *Cancer treatment reviews* **43**, 113-123 (2016).

33. Flaherty, D. C. et al. Prognostic utility of immunoprofiling in colon cancer: results from a prospective, multicenter nodal ultrastaging trial. *Journal of the American College of Surgeons* **223**, 134-140 (2016).

34. Zhang, Z. et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. **579**, 415-420, doi:10.1038/s41586-020-2071-9 (2020).

**Tables**

Table 1. Correlation between DFNA5 expression and clinical prognosis in head and neck squamous cell carcinoma with different clinicopathological factors using the Kaplan-Meier plotter.
| Clinicopathological characteristics | OS survival |
|-----------------------------------|------------|
|                                   | N | Hazard ratio | P-value |
| **Gender:**                       |   |             |         |
| Female                            | 133 | 1.56(0.95-2.55) | 0.076 |
| Male                              | 366 | 1.43(1.01-2.03) | 0.041 |
| **Race:**                         |   |             |         |
| White                             | 426 | 0.35(1.01-1.82) | 0.044 |
| black/African American            | 47  | 3.4(1.3-8.91)  | 0.0084 |
| 1                                 | 25  | 7.29(0.76-70.09) | 0.044 |
| **Stage**                         |   |             |         |
| 2                                 | 69  | 0.45(0.2-1)   | 0.043 |
| 3                                 | 78  | 1.55(0.68-3.55) | 0.29 |
| 4                                 | 259 | 1.75(1.21-2.53) | 0.0027 |
| 1                                 | 61  | 1.94(0.8-4.7)  | 0.14 |
| **Grade:**                        |   |             |         |
| 2                                 | 298 | 1.29(0.91-1.82) | 0.15 |
| 3                                 | 119 | 2.25(1.29-3.92) | 0.0033 |
| 4                                 | 7   |             |         |
| high                              | 251 | 1.34(0.91-1.98) | 0.14 |
| **Mutation burden:**              |   |             |         |
| low                               | 243 | 1.95(1.29-2.97) | 0.0014 |
| enriched                          | 243 | 1.7(1.11-2.6)  | 0.013 |
| **Basophils:**                    |   |             |         |
| decreased                         | 254 | 1.22(0.83-1.79) | 0.3 |
| enriched                          | 238 | 2.07(1.31-3.28) | 0.0015 |
| **B-cells:**                      |   |             |         |
| decreased                         | 259 | 1.16(0.77-1.73) | 0.48 |
| enriched                          | 316 | 1.66(1.16-2.37) | 0.0048 |
| **CD4+ memory T-cells:**          |   |             |         |
| decreased                         | 181 | 1.3(0.84-2.01)  | 0.24 |
| enriched                          | 305 | 1.55(1.05-2.27) | 0.025 |
| **CD8+ T-cells:**                 |   |             |         |
| decreased                         | 192 | 1.62(1.04-2.51) | 0.03 |
| enriched                          | 215 | 1.55(1.05-2.27) | 0.025 |
| **Eosinophils:**                  |   |             |         |
| decreased                         | 282 | 1.53(1.07-2.19) | 0.02 |
| enriched                          | 205 | 1.49(0.91-2.38) | 0.12 |
| **Macrophages:**                  |   |             |         |
| decreased                         | 292 | 1.34(0.93-1.94) | 0.12 |
| enriched                          | 313 | 1.62(1.15-2.27) | 0.0053 |
| Cell Type                      | Status     | Value       | p-value |
|-------------------------------|------------|-------------|---------|
| Mesenchymal stem cells:       | decreased  | 1.33(0.85-2.07) | 0.21   |
| enriched                      | 1.54(0.94-2.52) | 0.082      |
| Natural killer T-cells:       | decreased  | 1.36(0.97-1.9) | 0.077  |
| enriched                      | 1.43(1.01-2.01) | 0.04      |
| Regulatory T-cells:           | decreased  | 1.54(0.95-2.48) | 0.074  |
| enriched                      | 1.53(1.11-2.11) | 0.0082   |
| Type 1 T-helper cells:        | decreased  | 1.38(0.8-2.39) | 0.24   |
| enriched                      | 1.39(1.04-1.85) | 0.024     |
| Type 2 T-helper cells:        | decreased  | 4.84(0.8-29.1) | 0.057  |

**Figures**
Figure 1

DFNA5 expression in human head and neck squamous cell carcinoma (HNSCC). (A–D) The expression level of DFNA5 in HNSCCs and healthy tissues as calculated from the gene expression data of the Oncomine database (A), TIMER database (B), and RNA-sequencing data from the TCGA database processed using GEPIA (C, D). (E–I) Analysis of DFNA5 expression in different subtypes of HNSCC using gene expression data from the Oncomine database. *P < 0.05.
Figure 2

DFNA5 transcription analysis in subgroups of patients with HNSCC. (A) Relative expression levels of DFNA5 in normal and HNSCC samples. (B) Boxplot showing relative expression levels of DFNA5 in healthy individuals or in patients with HNSCC at stages 1, 2, 3 or 4. (C) Relative expression of DFNA5 in healthy individuals of any ethnicity or in HNSCC patients of Caucasian, African-American, or Asian ethnicity. (D) Boxplot showing relative expression levels of DFNA5 in healthy individuals of either gender or in male or female HNSCC patients. (E) Relative expression levels of DFNA5 in healthy individuals of any age or in HNSCC patients of different age groups. (F) Boxplot showing relative expression levels of DFNA5 in healthy individuals or in patients with HNSCC of grade 1, 2, 3, or 4. (G) Boxplot showing relative expression levels of DFNA5 in healthy individuals or in HNSCC patients with or without human papillomavirus (HPV) infection. (H) Boxplot showing the relative expression of DFNA5 in normal
individuals or in HNSCC patients based on nodal metastasis status. (I) In vitro validation of the expression level of DFNA5 in the HNSCC cell lines SCC-15 (ATCC CRL-1623), Cellosaurus HN6 (CVCL_8129), and human oral squamous cell carcinoma (HSC-3); human normal oral keratinocytes (NOKs) were used as control cells. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 3
Prognostic value of DFNA5 in HNSCC patients. (A–C) Correlation between overall survival (OS) and DFNA5 expression in patients with HNSCC as assessed using the Kaplan-Meier plotter (A), TISIDB (B), and UALCAN (C). (D–F) Correlation between OS and DFNA5 expression for patients of different tumor grades (D), races (E), and genders (F) as assessed using UALCAN. *P < 0.05.

Figure 4
Enrichment function analyses of co-expressed genes indicating an association of DFNA5 with cell adhesion. (A, B) Lists of the top 200 genes positively correlated with DFNA5 expression as determined using cBioPortal (A) and UALCAN (B). (C) Venn diagram of the two lists showing an intersection containing 125 genes. (D–F) GO enrichment in biological processes (D), cellular components (E), and molecular functions (F) for the 125 common genes. (G) KEGG pathway enrichment analysis of the 125 common genes.
Identification and analysis of DFNA5 positively correlated hub genes. (A) Top 10 hub genes as identified using the cytoHubba tool kit in Cytoscape. (B–K) Expression level and overall survival analyses for each of the 10 identified hub genes in head and neck squamous cell carcinoma patients. *P < 0.05.

Figure 6

Correlation analysis of DFNA5 expression and immune cell infiltration in HNSCC. (A) DFNA5 expression is significantly negatively correlated with infiltrated B cells and CD8+ T cells. (B) Correlation between DFNA5
and markers of various immune cells in Tumor Immune Estimation Resource (TIMER).